Vir Biotechnology, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Vir Biotechnology is a clinical-stage biopharmaceutical company that develops antibody- and T-cell-based therapies targeting infectious diseases and cancer, including programs for hepatitis B, hepatitis D, and HIV.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| de Verneuil VaninaEVP, General Counsel, Corp Sec | Sell | $15K | 1,343at $11.33 | Nov 2, 2026 |
| de Verneuil VaninaEVP, General Counsel, Corp Sec | Sell | $27K | 2,407at $11.10 | Nov 3, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable VIR activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.